Bristol-Myers Squibb strikes a $200 million deal with Isis Pharmaceuticals to further develop a new cholesterol drug, and Stanley Crooke, Isis Pharmaceuticals chairman & CEO, discusses the partnership with Mike Huckman, CNBC's pharmaceuticals reporter
Topics:
Biotechnology | Pharmaceuticals | Stock Market
COMMENTS
Thank you for joining our discussion. Your comment has been posted.
Data is a real-time snapshot *Data is delayed at least 15 minutes Market Data Terms of Service
Global Business and Financial News, Stock Quotes, and Market Data and Analysis
More Comments
ADD COMMENTS
PREVIEW COMMENT